| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/19/2007 | WO2007041936A1 Alkyl alcohol piperazine derivative optical isomers and their salts and applications thereof |
| 04/19/2007 | WO2007025249A3 Methods for treatment of headaches by administration of oxytocin |
| 04/19/2007 | WO2007025055A3 Benztropine compounds and uses thereof as dopamine uptake inhibitors |
| 04/19/2007 | WO2007021189A3 Method of treating parturient placental mammals in order to reduce maternal and/or utirine exhaustion |
| 04/19/2007 | WO2007017758A3 Novel cysteine protease inhibitors and their therapeutic applications |
| 04/19/2007 | WO2007017758A2 Novel cysteine protease inhibitors and their therapeutic applications |
| 04/19/2007 | WO2007017546A3 Method of obtaining tryptamine derivatives |
| 04/19/2007 | WO2007012870A3 Use of nefopam for the treatment of affective disorders |
| 04/19/2007 | WO2007009758A3 2r,4s) -4- (4-acetyl-3-hydroxy-1-piperazinyl) -n- { (1r) -1- [3, 5-bis (trifluoromethyl) phenyl] ethyl} -2- (4-fluoro-2-methylphenyl) -n-methyl-1-piperidine-carboxamide as tachykinin receptor antagonist |
| 04/19/2007 | WO2007000325A3 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-on- compounds and the use thereof for producing drugs |
| 04/19/2007 | WO2006136419A3 Use of urokinase inhibitors for the treatment and/or prevention of neuropathological diseases |
| 04/19/2007 | WO2006131322A3 Use op brivaracetam for the treatment of diseases characterized by progressive myoclonic epilepsy |
| 04/19/2007 | WO2006125616A3 Pyrimidine-based cdk inhibitors for treating pain |
| 04/19/2007 | WO2006076284A3 AMINO-IMIDAZOLONES FOR THE INHIBITION OF ß-SECRETASE |
| 04/19/2007 | WO2006040178A9 Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to madulation of the dopamine d3 receptor |
| 04/19/2007 | WO2006040153A3 Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| 04/19/2007 | WO2005081619A3 Compounds and methods for increasing neurogenesis |
| 04/19/2007 | WO2004091475A3 Gaucher disease drugs and methods of identifying same |
| 04/19/2007 | US20070088085 Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 04/19/2007 | US20070088068 E-series of prostaglandin (EP) receptors; reducing [4-(4,9-dipropoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetate to form [[4-(4,9-dipropoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl) phenyl]acetic acid |
| 04/19/2007 | US20070088059 Neuroprotectants; reduce side effect of neurotoxic agent; treatment of neuropathies resulting from chemotherapeutic agents used in the treatment of HIV and proliferative disease such as cancer and treatment of inflammatory diseases, neurodegenerative diseases |
| 04/19/2007 | US20070088052 Sulfonamide derivatives as 5ht7 receptor antagonists |
| 04/19/2007 | US20070088033 Diaryl Substituted Pyridinones |
| 04/19/2007 | US20070088008 treating psoriasis with e.g. 19-nor-2beta-ethyl-1alpha,25-dihydroxyvitamin D3 |
| 04/19/2007 | US20070088006 Preemptive Prophylaxis of Migraine |
| 04/19/2007 | US20070088005 Pharmaceutical compositions for headache, migraine, nausea and emesis |
| 04/19/2007 | US20070087969 Wound healing and treatment of fibrosis |
| 04/19/2007 | US20070087388 G protein coupled receptor |
| 04/19/2007 | US20070087342 Secreted proteins |
| 04/19/2007 | US20070087010 Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders |
| 04/19/2007 | CA2627623A1 Methods for inhibiting protein kinases |
| 04/19/2007 | CA2625974A1 Imidazole derivatives for the treatment of anxiety and related diseases |
| 04/19/2007 | CA2625763A1 Quaternary alpha-aminocarboxamide derivatives as modulators of voltage-gated sodium channels |
| 04/19/2007 | CA2625663A1 3,5-disubstituted phenyl-piperidines as modulators of dopamine neurotransmission |
| 04/19/2007 | CA2625642A1 Prolinamide derivatives as sodium channel modulators |
| 04/19/2007 | CA2625611A1 Imidazo benzodiazepine derivatives |
| 04/19/2007 | CA2625301A1 Isoxazole derivatives |
| 04/19/2007 | CA2624683A1 Modulators of atp-binding cassette transporters |
| 04/19/2007 | CA2624610A1 Kinase inhibitors |
| 04/19/2007 | CA2623535A1 Hexahydro cyclooctyl pyrazole cannabinoid modulators |
| 04/19/2007 | CA2623327A1 Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same |
| 04/19/2007 | CA2609116A1 Animal model of schizophrenia |
| 04/18/2007 | EP1775303A1 Topiramate and pharmaceutical compositions thereof |
| 04/18/2007 | EP1775297A2 Adenosine receptor antagonists and methods of making and using the same |
| 04/18/2007 | EP1775283A1 3-aminobenamide compound and vanilloid receptor 1 (vr1) activity inhibitor |
| 04/18/2007 | EP1774969A2 Controlled release oxycodone compositions |
| 04/18/2007 | EP1774968A1 Benzylisoquinoline derivative- or bisbenzylisoquinoline derivative-containing psychotropic agent, analgesic and/or antiphlogistic, and health food |
| 04/18/2007 | EP1774967A1 Solid oral dosage forms comprising valsartan |
| 04/18/2007 | EP1773985A1 Method for stimulating mammalian cells and mammalian cell |
| 04/18/2007 | EP1773844A1 Compounds having affinity for the dopamine d3 receptor and uses thereof in medicine |
| 04/18/2007 | EP1773833A2 Pyrrolo(oxo)quinolines as 5ht ligands |
| 04/18/2007 | EP1773827A1 Benzothiazole derivatives |
| 04/18/2007 | EP1773816A2 Modulators of atp-binding cassette transporters |
| 04/18/2007 | EP1773814A2 Substituted oxindol derivatives and medicaments containing the same |
| 04/18/2007 | EP1773810A1 New 4-benzylidene-piperidin derivatives |
| 04/18/2007 | EP1773805A1 Quinazolin-4-yl-piperidine and cinnolin-4-yl-piperidine derivatives as pde10 inhibitors for the treatment of cns disorders |
| 04/18/2007 | EP1773795A1 Substituted benzothiazoles |
| 04/18/2007 | EP1773788A2 Quinazoline derivatives |
| 04/18/2007 | EP1773772A1 New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission |
| 04/18/2007 | EP1773770A1 Indole-2-carboxamidine derivatives as nmda receptor antagonists |
| 04/18/2007 | EP1773757A1 Trpv1 agonists, formulations containing them and uses thereof |
| 04/18/2007 | EP1773740A1 Neurologically-active compounds |
| 04/18/2007 | EP1773375A1 Netrin-related compositions and uses |
| 04/18/2007 | EP1773357A2 Compositions and methods of use of dimer digallates |
| 04/18/2007 | EP1773335A2 Nanoparticle dispersion containing lactam compound |
| 04/18/2007 | EP1773322A1 Method for treating nervous system disorders and conditions |
| 04/18/2007 | EP1773321A2 Method for treating nervous system disorders and conditions |
| 04/18/2007 | EP1773320A1 Method for treating nervous system disorders and conditions |
| 04/18/2007 | EP1773316A1 Use of phenylethanolaminotetralines for preparing anxiolytic drugs |
| 04/18/2007 | EP1773315A1 Arylacetic acids and related compounds for treatment of alzheimer's disease |
| 04/18/2007 | EP1773311A1 A gastric retained dosage form of gabapentin |
| 04/18/2007 | EP1773306A1 Medicament for the treatment of central nervous system disorders |
| 04/18/2007 | EP1773297A1 Infusion and injection solution of levodopa |
| 04/18/2007 | EP1699468B1 Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis |
| 04/18/2007 | EP1583531B1 Heteroaryl-substituted pyrrolo[2, 3- b]pyridine derivatives as crf receptor antagonists |
| 04/18/2007 | EP1536782B1 Synergistic combination of an alpha-2-delta ligand and a pdev inhibitor for use in the treatment of pain |
| 04/18/2007 | EP1483243B1 Preparation of n1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines |
| 04/18/2007 | EP1476438B1 Oxa- and thiadiazoles and their use as metalloproteinase inhibitors |
| 04/18/2007 | EP1476162B1 Controlled synthesis of ziprasidone |
| 04/18/2007 | EP1458386B1 Aroyl pyrrole heteroeryl and methanols useful for treating a central nervous system disorder |
| 04/18/2007 | EP1455792B1 Ureas of 2-aminobenzothiazoles as adenosine modulators |
| 04/18/2007 | EP1453792B1 Amine 1,2- and 1,3-diol compounds and their use for treatment of alzheimer's disease |
| 04/18/2007 | EP1451161B1 Imidazopyridines, pyrimidines and triazines for enhancing cognition as gaba-a alpha 5 receptor subtype ligands |
| 04/18/2007 | EP1393727B1 Remedial agent for myelopathic disease |
| 04/18/2007 | EP1390022B1 Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno 2,3-d|pyrimidine for the treatment of pain |
| 04/18/2007 | EP1352063B1 Receptor nucleic acids and polypeptides |
| 04/18/2007 | EP1335976B1 Modifier of organelle metalbolism |
| 04/18/2007 | EP1326613B2 Use of substituted imidazo 1,2-a|pyridine-, imidazo ¬1,2-a|pyrimidine and imidazo ¬1,2-a|pyrazine-3-yl-amine derivatives for producing nos-inhibiting medicaments |
| 04/18/2007 | EP1324652B1 Transgenic drosophila melanogaster expressing beta amyloid |
| 04/18/2007 | EP1192261B1 22025, a novel human cyclic nucleotide phosphodiesterase |
| 04/18/2007 | EP1186296B1 Mag expression promoters |
| 04/18/2007 | EP1137408B1 Agent for lowering endothelin levels |
| 04/18/2007 | EP1052259B1 Novel optically active aminopentane derivative |
| 04/18/2007 | EP1002071B1 Human glial cell line-derived neurotrophic factor promoters, vectors containing same, and methods of screening compounds therewith |
| 04/18/2007 | EP0960117B1 FIBROBLAST GROWTH FACTOR HOMOLOGOUS FACTORS (FHFs) AND METHODS OF USE |
| 04/18/2007 | EP0765169B1 Pigment epithelium-derived factor: characterization, genomic organization and sequence of the pedf gene |
| 04/18/2007 | CN1950389A Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs |
| 04/18/2007 | CN1950372A 咪唑并吡啶化合物 Imidazopyridine compound |
| 04/18/2007 | CN1950371A Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands |
| 04/18/2007 | CN1950370A Enantiomer-pure hexahydro- pyrrolocyclopenta- pyridine derivatives |